TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of a primary Sjögren´s Syndrome~* ESSDAI score ≥ 6~* Liver values above 1,5 ULN~* Stable low dose systemic use of Glucocorticoids（\<=7.5mg） in the last 4 weeks before begin with Study medication~Exclusion Criteria:~* Secondary Sjögren's Syndrome~* Pre-treatment with Cyclosporine A~* Receiving cyclosphosphamide, corticosteroid bolus with dose over 1 mg/kg, rituximab, belimumab, other immunosuppressives~* Infection~* Neoplasia~* Relevant cardiac, pulmonary, neurologic or psychiatric disease~* Life-Vaccination within 4 weeks before begin with study medication~* Pregnant or breast-feeding~* Weight under 45kg or more than 80kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental: hrIL-2 active (Type: ACTIVE_COMPARATOR): Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
- Placebo Comparator: hrIL-2 placebo (Type: PLACEBO_COMPARATOR): 1 million U doses of placebo s.c. injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a diagnosis of severe intestinal GVHD that is not improving at any time after initial treatment with glucocorticoids for at least 7 days are eligible for enrollment; measures indicating severity of GVHD will include: a) persistent diarrhea with average daily stool volumes \> 500 mL per day; or b) persistent hemorrhage that is detectable by visual inspection of the stool~* Patients with denuded mucosa caused by GVHD are eligible for enrollment, regardless of prior treatment for acute GVHD; denuded mucosa is defined as loss (i.e., erosion or sloughing) of the epithelium in: a) at least one-third of the surface area in a 30 cm colonic segment (i.e., rectosigmoid, descending or transverse colon); or b) at least one fifth of the surface area of the second portion of the duodenum, as estimated by endoscopic evaluation; denuded mucosa must be documented by images of the duodenum and colon and by histologic evaluation of the colon~* All subjects must provide written informed consent with the use of forms approved by the Fred Hutchinson Cancer Research Center (FHCRC) Institutional Review Board (IRB)~Exclusion Criteria:~* Significant renal dysfunction (estimated creatinine clearance \< 30 mL/min)~* Persistent or recurrent malignancy~* Secondary malignancy~* Patients who had autologous or syngeneic marrow transplantation~* Presence of any cause of intestinal symptoms or ulceration other than GVHD~* Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven stage II or III pancreatic adenocarcinoma Ductal adenocarcinoma Mucinous noncystic carcinoma Signet ring cell carcinoma Adenosquamous carcinoma Undifferentiated (anaplastic) carcinoma Mixed ductal-endocrine carcinoma Well differentiated adenocarcinoma Moderately well or poorly differentiated adenocarcinoma Undifferentiated ductal carcinoma Must have unresectable and localized disease Measurable or evaluable disease~PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception Loss of no greater than 15% of actual body weight Oral intake of greater than 1,200 calories per day No other malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer, carcinoma in situ of the cervix, or any stage I or II cancer that is currently in complete remission~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic chemotherapy for pancreatic cancer Endocrine therapy: Not specified Radiotherapy: No prior radiation therapy for pancreatic cancer Surgery: At least 2 weeks since prior surgical bypass procedure and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-obese (body mass index = 18 - 25 kg/m\^2) or Obese (body mass index ≥ 30 kg/m\^2~* Any race or ethnicity~* Native English speaker~Exclusion Criteria:~* Past or current diabetes~* Current psychotropic medication use~* Past or current neurological illness~* Past or current substance or alcohol misuse~* Past or current mental illness~* Current binge eating disorder~* Magnetic resonance imaging contraindications~* Pregnancy~* Currently lactating~* Tobacco use within past month~* Over 350 lb

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Normal-weight (Type: ACTIVE_COMPARATOR): Participants who have a body mass index within the normal-weight category.
- Obese (Type: ACTIVE_COMPARATOR): Participants who have a body mass index within the obese category.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Arresting Vertical Transmission of Hepatitis B Virus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Pregnant women receiving care at Binza and Kingasani maternity centers presenting prior to 24 weeks gestation~* Infants born to HBV-positive women~Exclusion criteria:~* Participants who are severely sick and who require prolonged hospitalization.~* Any women who do not intend to stay in Kinshasa for prenatal care through delivery

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk HBV dyads (Type: EXPERIMENTAL): Mothers with high-risk HBV (defined as viral load \>10\^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
- Low-risk HBV dyads (Type: EXPERIMENTAL): Mothers with low risk HBV (defined as a viral load \<10\^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adult Patients Undergoing Open Colectomy MA402S23B303

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and older.~* Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.~* Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.~Exclusion Criteria:~* Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.~* Patients who abuse alcohol or other drug substance.~* Patients with severe hepatic impairment.~* Patients currently pregnant or who may become pregnant during the course of the study.~* Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.~* Patients who have participated in an EXPAREL study within the last 30 days.~* Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.~* Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery~In addition, the patient will be ineligible if he/she meets the following criteria during surgery:~* Patients who have any concurrent surgical procedure.~* Patients with unplanned multiple segmental resections or large intestine.~* Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.~* Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.~* Patients who receive Entereg(R).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV morphine sulfate (Type: ACTIVE_COMPARATOR): Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
- EXPAREL (bupivacaine liposome injectable suspension) (Type: EXPERIMENTAL): EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 18-50y,~* BMI 18-27,~* caucasian origin,~* type 1 diabetes diagnosed between age 5 and age 40,~* no known diabetes complications or cardiovascular diseases,~* no medication known to influence glucose homeostasis,~* no pregnancy~Exclusion Criteria:~* diabetes complications,~* autonomous nerve dysfunction,~* anaemia,~* HbA1c \< 8.5% at screening,~* estimated by the investigator to be incapable of completing the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- type 1 DM with betacell function: Liraglutide (Type: EXPERIMENTAL): None
- type 1 DM without betacell function: Liraglutide (Type: EXPERIMENTAL): None
- type 1 DM without betacell function: Insulin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes Remote Intervention to improVe Use of Evidence-based Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 27 - 79 years at the time of agreeing to participate in the program~2. Presence of type 2 diabetes (treated with metformin unless intolerant, may also be treated with DPP4i, sulfonylurea, pioglitazone, and/or basal insulin)~3. HbA1c 6.5-8.9%; AND~4. At elevated cardiovascular and/or renal risk defined as any diagnosed ASCVD, estimated ASCVD risk \>10%, congestive heart failure, non-alcoholic fatty liver disease, estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2, albuminuria above 300mg/g; and those aged 60 years or older with at least two of: active tobacco use, dyslipidemia (LDL-c above 160 mg/dL or 4.1 mmol/L, non-HDL-C above 190 mg/dL or 4.9 mmol/L, triglycerides above 175 mg/dL,) hypertension (2 systolic blood pressure values above 130 mmHg and/or 2 diastolic blood pressure values above 90 mmHg within 12 months,) or BMI above 30~5. Has seen a primary care provider within the Mass General Brigham network within the last year~Exclusion Criteria:~1. Type 1 diabetes~2. Currently or previously prescribed an SGLT2i or GLP1-RA~3. Taking any short-acting insulin~4. History of diabetic ketoacidosis~5. History of hypoglycemia requiring hospitalization~6. Frequent (more than two times in 1 week) episodes of symptomatic hypoglycemia with blood glucose \<70 mg/dL~7. eGFR below 15 ml/min/m2~8. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation, OR~9. Life expectancy less than 1 year or utilizing palliative care

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Medication & Education-First (Type: ACTIVE_COMPARATOR): Patient will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm.
- Education-First (Type: EXPERIMENTAL): Patient will first receive curated patient education, an alert to providers, and provider education, and then after 2 months begin participation in the remote clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes,~* Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1,~* HbA1c \>6.5% and ≤10.0%~Exclusion Criteria:~* Type 1 diabetes,~* history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,~* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: EXPERIMENTAL): None
- Glipizide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects, aged 18 to 75 years old, inclusive.~* Subjects with acromegaly defined as documented evidence of growth hormone-secreting pituitary tumor that is abnormally responsive to glucose, or documented elevated insulin-like growth factor-1 (IGF-1), who are currently receiving a stable dose of a somatostatin analog for at least the previous 3 months.~* A serum IGF-1 level \< 1.3 x the upper limit of normal (ULN) and a serum growth hormone (GH) level \< 2.5 ng/mL.~* Subjects able and willing to comply with the requirements of the protocol.~* Subjects able to swallow capsules.~* Subjects able to understand and sign written informed consent to participate in the study.~Exclusion Criteria:~* Receiving regular injections of a somatostatin analog less frequently than once a month, ie, longer than every 4 weeks.~* Symptomatic cholelithiasis.~* Received pituitary radiotherapy within ten years prior to screening.~* Undergone pituitary surgery within the prior 6 months.~* Any condition that may jeopardize study participation.~* Clinically significant gastrointestinal (GI), renal, or hepatic disease as determined by the Investigator.~* Conditions (eg, bariatric surgery) significantly affecting gastric acidity or emptying.~* Current use (within 1 month) of proton pump inhibitors (PPIs) and current chronic use of H2-antagonists.~* Female patients who are pregnant or lactating.~* Current or recent (\< 3 months) therapy with pegvisomant.~* Current or recent (\< 2 months) therapy with cabergoline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Octreotide capsules (Type: EXPERIMENTAL): Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Documented history of CrCl \<50 ml/min within the 3 months prior to enrollment~* HbA1c ≥7.0% and ≤11.0%~Exclusion Criteria:~* Type 1 diabetes, history of diabetic ketoacidosis or hyposmolar non-ketonic coma~* Previous or current treatment with any DPP-IV inhibitor and/or GLP-1 mimetic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxa (Type: EXPERIMENTAL): Saxagliptin
- Placebo (Type: NO_INTERVENTION): Placebo to match

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years the day of inclusion~* Mechanical ventilation through an endotracheal tube for more than three consecutive days (72h)~* Written informed consent of the patient or a proxy~* Patients covered by or having the rights to French social security~* Negative pregnancy test, at the time of inclusion, in women of childbearing potential~Exclusion Criteria:~* Suspicion or confirmed VAP the day of inclusion~* Clinical indication for systemic aminoglycoside therapy the day of inclusion : as deemed necessary by the clinician in charge~* Stage 2 or 3 KDIGO\* classification acute kidney injury the day of inclusion excepted in patients undergoing renal replacement therapy~* Chronic kidney failure : baseline glomerular filtration lower than 30 mL/min~* Patient scheduled for extubation within the next 24h~* Patient ventilated through an endotracheal tube for more than four consecutive days before inclusion (96h)~* Patient ventilated through a tracheostomy~* Patients allergic to aminoglycosides~* Myasthenia gravis~* Known pregnant women at the time of inclusion and lactating patients~* Known guardianship or trusteeship at the time of inclusion~* Patients previously included in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled amikacin (Type: EXPERIMENTAL): Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
- Placebo (Type: PLACEBO_COMPARATOR): Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants 0-6 months of age who require a thoracotomy for lung resection.~2. Parents accept the placement of an epidural catheter.~Exclusion Criteria:~1. Premature infants~2. Patients allergic to fentanyl and/or bupivacaine.~3. Known medical contraindications. -

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Fentanyl added to Bupivacaine via epidural catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete